IP Library Granted Patent US 10,758,502
Granted Patent B2
US 10,758,502 · App. 15/835,935 · Granted Sep 1, 2020

High concentration local anesthetic formulations

Inventors: James N. Campbell (Baltimore, MD); Arthur F. Michaelis (Baltimore, MD)
Assignee: Centrexion Therapeutics Corporation
A61K31/167A61K9/0014A61K9/0019A61K9/06A61K31/245A61K31/445A61K31/47A61K47/10A61K47/22A61K47/38
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,758,502
App. No.
15/835,935
Granted
Sep 1, 2020
Kind
B2
Abstract

A transdermal topical anesthetic formulation, which can be used to ameliorate or inhibit pain, has been developed. In the preferred embodiment, the topical anesthetic is a local anesthetic such as lidocaine, most preferably lidocaine free-base in a gel, and the dosage of the local anesthetic is effective in the painful area or immediately adjacent areas, to ameliorate or eliminate the pain. High concentration of local anesthetic in solution in the carrier is used to drive rapid release and uptake of the drug. Relief is typically obtained for a period of several hours.

Claims (22)

1. A method of treating pain, comprising topically administering an effective amount of a formulation to a site in need thereof for treating pain,

wherein the formulation comprises a free base caine alkaloid local anesthetic, diglycol monoethyl ether, and propylene glycol in a lotion, cream, or gel, the free base caine alkaloid local anesthetic is lidocaine free base which is present in an amount from greater than 20% by weight of the formulation, the formulation releases the largest dose of free base caine alkaloid local anesthetic from 0 to 8 hours after administration of the formulation to the site, and the formulation also comprises isopropyl myristate and/or dimethyl isosorbide.

2. The method of claim 1 wherein the free base caine alkaloid local anesthetic is present in an amount between greater than 20% and 40% by weight.

3. The method of claim 1 wherein the free base caine alkaloid local anesthetic is present in an amount of approximately 40% by weight.

4. The method of claim 1 providing an initial burst release within two hours of administration.

5. The method of claim 1 providing an initial burst release within four hours of administration.

6. The method of claim 1 providing an initial burst release within six hours of administration.

7. The method of claim 1 wherein the concentration of the free base caine alkaloid local anesthetic is sufficiently high that release is governed by the Second Law of Thermodynamics, not simple diffusion.

8. The method of claim 1 for administration to wounds, abrasions, or burns.

9. The method of claim 1 wherein the formulation is a gel.

10. The method of claim 1 wherein the formulation is a non-aqueous gel.

11. The method of claim 9 wherein the free base caine alkaloid local anesthetic is present in an amount from greater than 20% to about 40% by weight of the formulation.

12. The method of claim 9 wherein the free base caine alkaloid local anesthetic is present in an amount of about 40% by weight of the formulation.

13. The method of claim 9 wherein the formulation further comprises ethanol and hydroxypropyl cellulose.

14. The method of claim 13 wherein the formulation comprises isopropyl myristate.

15. The method of claim 13 wherein the formulation comprises dimethyl isosorbide.

16. The method of claim 1 wherein the formulation is a gel containing 40% w/w lidocaine free base, 20% w/w diglycol monoethyl ether, 10% w/w propylene glycol, 10% w/w dimethyl isosorbide, 18.80% w/w ethanol, and 1.2% w/w hydroxypropyl cellulose.

17. The method of claim 1 wherein the formulation releases the largest dose of free base caine alkaloid local anesthetic from 0 to 6 hours after administration to the site.

18. The method of claim 1 wherein the pain is neuropathic pain.

19. The method of claim 3 wherein the pain is neuropathic pain.

20. The method of claim 1 wherein the pain is non-neuropathic pain.

21. The method of claim 3 wherein the pain is non-neuropathic pain.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Nov 21, 2025
From: AVENUE VENTURE OPPORTUNITIES FUND, L.P., AS AGENT
To: CENTREXION THERAPEUTICS CORPORATION
Reel/Frame 073683/0099 →
SECURITY INTEREST Recorded Jul 12, 2023
From: CENTREXION THERAPEUTICS CORPORATION
To: AVENUE VENTURE OPPORTUNITIES FUND, L.P., AS AGENT
Reel/Frame 064256/0125 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 5, 2018
From: CAMPBELL, JAMES N.; MICHAELIS, ARTHUR F.
To: ARCION THERAPEUTICS, INC.
Reel/Frame 046785/0964 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 5, 2018
From: ARCION THERAPEUTICS, INC.
To: VALLINEX, INC.
Reel/Frame 046785/0972 →
MERGER Recorded Sep 5, 2018
From: VALLINEX, INC.
To: CENTREXION I, INC.
Reel/Frame 046785/0984 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 5, 2018
From: CENTREXION I, INC.
To: CENTREXION THERAPEUTICS CORPORATION
Reel/Frame 046786/0020 →
Continuity (5)
Continuation 15184012 · Jun 16, 2016
Continuation 13401088 · Feb 21, 2012
Continuation 12542365 · Aug 17, 2009
Provisional Application 61089348 · Aug 15, 2008
Related Publication 20180296506A1 · Oct 18, 2018